Emicizumab, the bispecific antibody to factors IX/IXa and X/Xa, potentiates coagulation function in factor XI ‐deficient plasma in vitro

ConclusionEmicizumab appeared to improve coagulation function in severe FXI ‐deficient plasma, and might provide possibilities for clinical application in the patients with FXI deficiency.This article is protected by copyright. All rights reserved.

Source: Journal of Thrombosis and Haemostasis - November 16, 2018 Category: Hematology Authors: Hiroaki Minami, Keiji Nogami, Koji Yada, Kenichi Ogiwara, Shoko Furukawa, Tetsuhiro Soeda, Takehisa Kitazawa, Midori Shima Tags: Original Article ‐ Coagulation Source Type: research